Search

Displaying results 1981 - 1990 of 4590 in total
  1. Drug

    Ioforminol

    go.drugbank.com/drugs/DB12439
    Investigational

    Ioforminol has been used in trials studying the diagnostic of Cardio Renal Safety in High-risk Elderly Subjects Undergoing a Coronary CATH With or Without PCI.

  2. Drug

    Thiamine

    go.drugbank.com/drugs/DB00152
    ApprovedInvestigationalNutraceuticalVet approved

    Thiamine was first discovered by Umetaro Suzuki in Japan when researching how rice bran cured patients of Beriberi.

    Mixtures: High Potency Vitamin B Complex + C Tab, High Potency Multivitamins & Minerals Caplets
  3. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019. … By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.[L43277] Niraparib is selective towards PARP-1 and PARP-2.

  4. Drug

    Topsalysin

    go.drugbank.com/drugs/DB05160
    Investigational

    Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.

  5. Drug

    Tea tree oil

    go.drugbank.com/drugs/DB11218
    ApprovedNutraceutical

    The dermatological use of tea tree oil has been investigated by various studies, where several studies have suggested the uses of this oil for the treatment of acne vulgaris, seborrheic dermatitis, and

  6. Drug

    Urea C-14

    go.drugbank.com/drugs/DB09513
    ApprovedInvestigational

    To detect H. pylori, urea labeled with 14C is swallowed by the patient.

  7. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    However, patients with certain types of B-cell lymphoma, such as follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) or aggressive B-cell lymphoma, have a high probability of relapse or recurrence

  8. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients.

  9. Drug

    Interferon alfa-2b

    go.drugbank.com/drugs/DB00105
    ApprovedInvestigational

    This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.

  10. Drug

    Dalfopristin

    go.drugbank.com/drugs/DB01764
    Approved

    Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.